Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay
CEO & Managing Director, Dr Steven Gourlay
Source: Steven Gourlay/LinkedIn
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Actinogen Medical (ACW) finalises the designs for its planned phase two trials in Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD)
  • The trials will be testing the company’s lead compound, Xanamem, as a new therapy for AD and depression
  • The AD part B phase two trial will run for six months and is testing around 300 patients with results expected next year
  • The MDD phase two trial will be a six week trial, testing around 120 patients, with results expected at the end of the year
  • ACW shares are down 1.67 per cent on the market this afternoon to trade at 5.9 cents per share at market close

Actinogen Medical (ACW) has finalised the designs for its planned phase two trials in Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD).

The trials will be testing the company’s lead compound, Xanamem, as a new therapy for AD and depression.

Alzheimers Disease

The XanaMIA part B phase two trial will be a six-month dose-ranging, placebo-controlled trial.

It will be testing the drug on around 300 patients with early stage AD, including mild cognitive impairment patients.

The doses of Xanamem will be measured by the same cogstate cognitive test battery used in the part A trial.

Actinogen is expecting to receive results from the trial in 2024.

Major Depressive Disorder

The MDD phase two trial will be a six-week trial, testing around 120 patients with MDD and cognitive difficulties.

Xanamem will be added to exisiting anti-depressant therapy and effects on both depression and cognition will be assessed.

Results are expected in late 2023.

“We are now initiating two robust phase two trials in patients with Alzheimer’s Disease and Depression,” CEO Steven Gourlay said.

“Xanamem has the potential to be an effective low-dose daily oral therapy for these and many conditions where it may be used alone or in combination with other treatments.”

ACW shares were down 1.67 per cent on the market this afternoon to trade at 5.9 cents per share at market close.

ACW by the numbers
More From The Market Online

Australia and New Zealand seen as top places for business

Australia has moved up the ranks in terms of its 'reputation' and ease of doing business,…
The Market Online Video

Bitcoin: what’s driving the major comeback?

Why is bitcoin suddenly making a comeback after a dormant couple of years? Watch the video above…
The Market Online Video

Market Close: Autumn’s ASX200 record breaking start

The ASX200 has closed the first day of Autumn at a new record 7745.6 points -…